Cargando…

Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease

BACKGROUND: Studies have demonstrated a potential role for fecal biomarkers such as fecal calprotectin (FC) and fecal lactoferrin (FL) in monitoring inflammatory bowel diseases (IBD) - Crohn’s disease (CD) and ulcerative colitis (UC). However, their correlation to endoscopic scores, disease severity...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio, Marrieth G, Amo-Mensah, Kofi, Gray, James M, Nguyen, Vu Q, Nakat, Sam, Grider, Douglas, Love, Kim, Boone, James H, Sorrentino, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940564/
https://www.ncbi.nlm.nih.gov/pubmed/31911845
http://dx.doi.org/10.4291/wjgp.v10.i5.54
_version_ 1783484359637991424
author Rubio, Marrieth G
Amo-Mensah, Kofi
Gray, James M
Nguyen, Vu Q
Nakat, Sam
Grider, Douglas
Love, Kim
Boone, James H
Sorrentino, Dario
author_facet Rubio, Marrieth G
Amo-Mensah, Kofi
Gray, James M
Nguyen, Vu Q
Nakat, Sam
Grider, Douglas
Love, Kim
Boone, James H
Sorrentino, Dario
author_sort Rubio, Marrieth G
collection PubMed
description BACKGROUND: Studies have demonstrated a potential role for fecal biomarkers such as fecal calprotectin (FC) and fecal lactoferrin (FL) in monitoring inflammatory bowel diseases (IBD) - Crohn’s disease (CD) and ulcerative colitis (UC). However, their correlation to endoscopic scores, disease severity and affected intestinal surface has not been extensively investigated. AIM: To correlate FL, and for comparison white blood cell (WBC) and C-reactive protein (CRP), with endoscopic scores, disease extent and location in CD and UC. METHODS: Retrospective analysis in 188 patients who had FL, CRP and WBC determined within 30 d of endoscopy. Disease location, disease extent (number of intestinal segments involved), disease severity (determined by endoscopic scores), timing of FL testing in relation to colonoscopy, as well as the use of effective fast acting medications (steroids and biologics) between colonoscopy and FL measurement, were recorded. RESULTS: In 131 CD and 57 UC patients, both CRP and FL - but not WBC - distinguished disease severity (inactive, mild, moderate, severe). In patients receiving fast-acting (steroids or biologics) treatment in between FL and colonoscopy, FL showed a higher correlation to endoscopic scores when tested before vs after the procedure (r = 0.596, P < 0.001, vs r = 0.285, P = 0.15 for the Simple Endoscopic Score for CD; and r = 0.402, P = 0.01 vs r = 0.054 P = 0.84 for Disease Activity Index). Finally, FL was significantly correlated with the diseased mucosal surface (colon-ileocolon > small bowel) and the number of inflamed colon segments. CONCLUSION: FL and CRP separated disease severity categories with FL showing lower discriminating P-values. FL showed a close correlation with the involved mucosal surface and with disease extent and was more closely correlated to endoscopy when determined before the procedure – this indicating that inflammatory activity changes associated with therapy might be rapidly reflected by FL levels. FL can accurately and timely characterize intestinal inflammation in IBD.
format Online
Article
Text
id pubmed-6940564
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-69405642020-01-07 Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease Rubio, Marrieth G Amo-Mensah, Kofi Gray, James M Nguyen, Vu Q Nakat, Sam Grider, Douglas Love, Kim Boone, James H Sorrentino, Dario World J Gastrointest Pathophysiol Retrospective Cohort Study BACKGROUND: Studies have demonstrated a potential role for fecal biomarkers such as fecal calprotectin (FC) and fecal lactoferrin (FL) in monitoring inflammatory bowel diseases (IBD) - Crohn’s disease (CD) and ulcerative colitis (UC). However, their correlation to endoscopic scores, disease severity and affected intestinal surface has not been extensively investigated. AIM: To correlate FL, and for comparison white blood cell (WBC) and C-reactive protein (CRP), with endoscopic scores, disease extent and location in CD and UC. METHODS: Retrospective analysis in 188 patients who had FL, CRP and WBC determined within 30 d of endoscopy. Disease location, disease extent (number of intestinal segments involved), disease severity (determined by endoscopic scores), timing of FL testing in relation to colonoscopy, as well as the use of effective fast acting medications (steroids and biologics) between colonoscopy and FL measurement, were recorded. RESULTS: In 131 CD and 57 UC patients, both CRP and FL - but not WBC - distinguished disease severity (inactive, mild, moderate, severe). In patients receiving fast-acting (steroids or biologics) treatment in between FL and colonoscopy, FL showed a higher correlation to endoscopic scores when tested before vs after the procedure (r = 0.596, P < 0.001, vs r = 0.285, P = 0.15 for the Simple Endoscopic Score for CD; and r = 0.402, P = 0.01 vs r = 0.054 P = 0.84 for Disease Activity Index). Finally, FL was significantly correlated with the diseased mucosal surface (colon-ileocolon > small bowel) and the number of inflamed colon segments. CONCLUSION: FL and CRP separated disease severity categories with FL showing lower discriminating P-values. FL showed a close correlation with the involved mucosal surface and with disease extent and was more closely correlated to endoscopy when determined before the procedure – this indicating that inflammatory activity changes associated with therapy might be rapidly reflected by FL levels. FL can accurately and timely characterize intestinal inflammation in IBD. Baishideng Publishing Group Inc 2019-12-31 2019-12-31 /pmc/articles/PMC6940564/ /pubmed/31911845 http://dx.doi.org/10.4291/wjgp.v10.i5.54 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Cohort Study
Rubio, Marrieth G
Amo-Mensah, Kofi
Gray, James M
Nguyen, Vu Q
Nakat, Sam
Grider, Douglas
Love, Kim
Boone, James H
Sorrentino, Dario
Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
title Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
title_full Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
title_fullStr Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
title_full_unstemmed Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
title_short Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
title_sort fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940564/
https://www.ncbi.nlm.nih.gov/pubmed/31911845
http://dx.doi.org/10.4291/wjgp.v10.i5.54
work_keys_str_mv AT rubiomarriethg fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT amomensahkofi fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT grayjamesm fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT nguyenvuq fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT nakatsam fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT griderdouglas fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT lovekim fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT boonejamesh fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease
AT sorrentinodario fecallactoferrinaccuratelyreflectsmucosalinflammationininflammatoryboweldisease